MANNKIND CORP Accrued Liabilities, Current
MANNKIND CORP (MNKD) had Accrued Liabilities, Current of $60.77 million as of 2026-06-30, per its 10-Q filed 2026-08-05.
Financial Statements › Balance Sheet › Liabilities › Liabilities, Current › Accounts Payable and Accrued Liabilities, Current › Accrued Liabilities, Current
us-gaap:AccruedLiabilitiesCurrent · last filed 2026-08-05
- 2026-06-30: Accrued Liabilities, Current $60.77M.
- 2026-03-31: Accrued Liabilities, Current $58.60M.
- 2025-12-31: Accrued Liabilities, Current $64.63M.
- 2025-09-30: Accrued Liabilities, Current $31.42M.
| Period end | Accrued Liabilities, Current |
|---|---|
| 2026-06-30 | $60.77M 10-Q · filed 2026-08-05 |
| 2026-03-31 | $58.60M 10-Q · filed 2026-05-06 |
| 2025-12-31 | $64.63M 10-Q · filed 2026-08-05 |
| 2025-09-30 | $31.42M 10-Q · filed 2025-11-05 |
| 2025-06-30 | $30.91M 10-Q · filed 2025-08-06 |
| 2025-03-31 | $40.10M 10-Q · filed 2025-05-08 |
| 2024-12-31 | $40.29M 10-K · filed 2026-02-26 |
| 2024-09-30 | $37.39M 10-Q · filed 2024-11-07 |
| 2024-06-30 | $40.95M 10-Q · filed 2024-08-07 |
| 2024-03-31 | $42.29M 10-Q · filed 2024-05-08 |
| 2023-12-31 | $42.04M 10-K · filed 2025-02-26 |
| 2023-09-30 | $32.10M 10-Q · filed 2023-11-07 |
| 2023-06-30 | $36.83M 10-Q · filed 2023-08-07 |
| 2023-03-31 | $32.99M 10-Q · filed 2023-05-09 |
| 2022-12-31 | $35.55M 10-K · filed 2024-02-27 |
| 2022-09-30 | $30.35M 10-Q · filed 2022-11-08 |
| 2022-06-30 | $33.18M 10-Q · filed 2022-08-09 |
| 2022-03-31 | $27.13M 10-Q · filed 2022-05-05 |
| 2021-12-31 | $27.42M 10-K · filed 2023-02-23 |
| 2021-09-30 | $20.83M 10-Q · filed 2021-11-09 |
| 2021-06-30 | $22.41M 10-Q · filed 2021-08-11 |
| 2021-03-31 | $27.59M 10-Q · filed 2021-05-12 |
| 2020-12-31 | $19.71M 10-K · filed 2022-02-24 |
| 2020-09-30 | $15.81M 10-Q · filed 2020-11-04 |
| 2020-06-30 | $14.71M 10-Q · filed 2020-08-05 |
| 2020-03-31 | $18.33M 10-Q · filed 2020-05-06 |
| 2019-12-31 | $15.90M 10-K · filed 2021-02-25 |
| 2019-09-30 | $14.30M 10-Q · filed 2019-11-08 |
| 2019-06-30 | $16.45M 10-Q · filed 2019-08-07 |
| 2019-03-31 | $18.06M 10-Q · filed 2019-05-07 |
| 2018-12-31 | $15.02M 10-K · filed 2020-02-25 |
| 2018-09-30 | $13.43M 10-Q · filed 2018-11-01 |
| 2018-06-30 | $14.07M 10-Q · filed 2018-08-02 |
| 2018-03-31 | $15.93M 10-Q · filed 2018-05-09 |
| 2017-12-31 | $12.45M 10-K · filed 2019-02-26 |
| 2017-09-30 | $12.49M 10-Q · filed 2017-11-07 |
| 2017-06-30 | $9.08M 10-Q · filed 2017-08-07 |
| 2017-03-31 | $10.66M 10-Q · filed 2017-05-10 |
| 2016-12-31 | $7.94M 10-K · filed 2018-02-27 |
| 2016-09-30 | $14.16M 10-Q · filed 2016-11-09 |
| 2016-06-30 | $10.25M 10-Q/A · filed 2016-08-10 |
| 2016-03-31 | $8.08M 10-Q · filed 2016-05-09 |
| 2015-12-31 | $7.93M 10-K · filed 2017-03-16 |
| 2015-09-30 | $14.08M 10-Q · filed 2015-11-09 |
| 2015-06-30 | $13.93M 10-Q · filed 2015-08-10 |
| 2015-03-31 | $12.38M 10-Q · filed 2015-05-11 |
| 2014-12-31 | $26.21M 10-K · filed 2016-03-15 |
| 2014-09-30 | $27.27M 10-Q · filed 2014-11-10 |
| 2014-06-30 | $20.58M 10-Q · filed 2014-08-11 |
| 2014-03-31 | $15.01M 10-Q · filed 2014-05-12 |
| 2013-12-31 | $21.63M 10-K · filed 2015-03-02 |
| 2013-09-30 | $21.55M 10-Q · filed 2013-11-12 |
| 2013-06-30 | $26.98M 10-Q · filed 2013-08-09 |
| 2013-03-31 | $26.38M 10-Q · filed 2013-05-10 |
| 2012-12-31 | $25.78M 10-K · filed 2014-03-03 |
| 2012-09-30 | $48.60M 10-Q · filed 2012-11-09 |
| 2012-06-30 | $49.62M 10-Q · filed 2012-08-09 |
| 2012-03-31 | $31.75M 10-Q · filed 2012-05-10 |
| 2011-12-31 | $20.74M 10-K · filed 2013-03-18 |
| 2011-09-30 | $15.71M 10-Q · filed 2011-11-04 |
| 2011-06-30 | $19.96M 10-Q · filed 2011-08-04 |
| 2010-12-31 | $14.84M 10-K · filed 2012-03-15 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| Alto Neuroscience, Inc. (ANRO) | United States | $1.065B | -11.02 |
| Savara Inc (SVRA) | United States | $1.044B | -9.10 |
| MoonLake Immunotherapeutics (MLTX) | Switzerland | $1.031B | -5.43 |
| Pacira BioSciences, Inc. (PCRX) | United States | $1.020B | 69.03 |
| Janux Therapeutics, Inc. (JANX) | United States | $1.019B | -9.15 |
| Amphastar Pharmaceuticals, Inc. (AMPH) | United States | $1.116B | 10.93 |
| Corvus Pharmaceuticals, Inc. (CRVS) | United States | $0.994B | -23.25 |
| Seaport Therapeutics, Inc. (SPTX) | United States | $1.131B | |
| Kura Oncology, Inc. (KURA) | United States | $0.967B | -3.29 |
| Arbutus Biopharma Corp (ABUS) | $0.965B | 6.19 |